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The lay summary: 
 
The amount of exercise/physical activity to benefit fatty liver disease in non alcoholic 
fatty liver disease (NAFLD) is not known. In a large study of free-living people, our 
aim was to determine the amount of exercise that was linked with a decrease in new 
fatty liver and also improvement of existing fatty liver over 5 years of follow up. 
Compared to no exercise, exercise ≥5 times per week (lasting at least 10 minutes on 
each occasion) was linked to a highly significantly benefit for both a decrease in new 
fatty liver and also improvement of existing fatty liver. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract=246 words 
Background & Aims Guidelines about recommendations for amounts of 
exercise/physical activity are variable in non alcoholic fatty liver disease (NAFLD). Our 
aim was to determine the amount of exercise that was associated with two outcomes: 
a) development of incident liver fat and b) resolution of baseline liver fat, at five year 
follow-up. 
Methods In an occupational health screening program, weekly frequency of exercise 
was assessed using the validated Korean version of the International Physical 
Activity Questionnaire Short Form (IPAQ-SF). Liver fat was identified by 
ultrasonography (3.5MHz probe) at baseline and at five year follow up. Fully adjusted 
Cox proportional hazards models were used to estimate hazard ratios (HRs and 95% 
confidence intervals) for incident fatty liver and resolution of fatty liver at follow up. 
Results 233,676 men and women were studied between 2002 and 2014. 126,811 
individuals were identified without fatty liver, and of these subjects, 29014 subjects 
developed incident fatty liver during follow up. At baseline, there were 42,536 
individuals with liver fat and of these individuals, fatty liver resolved in 14,514, during 
follow up. After full adjustment, compared to no exercise, exercise was associated 
with benefit for both outcomes; for exercise ≥5 times per week for incident fatty liver: 
HR 0.86 (95%CIs 0.80,0.92), p<0.001, and for resolution of fatty liver HR 1.40 
(95%CIs 1.25,1.55), p<0.001.   
Conclusions Moderate to vigorous exercise is beneficial in decreasing risk of 
development of new fatty liver or improving resolution of existing fatty liver during 5 
years of follow up. 
  
Introduction 
It is now accepted that the clinical burden of non-alcoholic fatty liver disease 
(NAFLD) extends beyond liver-related morbidity and mortality, with the concept that 
NAFLD is a multisystem disease that also affects several extra-hepatic organs and 
regulatory pathways[1] [2]. Incidence rates for NAFLD are uncertain (because of 
difficulties with establishing a precise diagnosis during sequential follow-up) but 
current incidence rates are approximately 20/10,000 person-years, peaking in the 
sixth decade of life with NAFLD being more common in men [3]. NAFLD comprises a 
complex spectrum of disease that begins with liver fat accumulation (non alcoholic 
fatty liver or NAFL) and progress with inflammation and fibrosis (non alcoholic 
steatohepatitis or NASH). There is now a wealth of evidence that NAFLD increases 
risk of type 2 diabetes (summarised in [1, 4]) but there is limited evidence to date 
that treatment of NAFLD decreases risk of T2DM. We have shown previously that 
resolution of fatty liver (detected by ultrasound) over 5 years, was independently 
associated with marked attenuation of the risk of incident T2DM [5] and also incident 
hypertension [6], over five years of follow up. Recently our findings for attenuation of 
the risk of T2DM has been verified in a Japanese population (that also confirmed the 
resolution of liver fat by ultrasonography) [7]. In contrast to previous notions that 
NAFL did not cause serious chronic liver disease, increasing evidence is now 
showing that NAFL is not harmless. Recently it has been shown that NAFL is an 
important risk factor for the development of clinically relevant liver fibrosis[8-11] and 
consequently it is now being realized that it is important to understand what 
interventions and treatments are effective for decreasing liver fat[12] within the 
spectrum of liver disease in NAFLD.  
 
In short duration studies, lifestyle changes that have focussed on diet and exercise 
modification have shown promise in decreasing liver fat as a manifestation of early 
disease in NAFLD [13-16].  However, guidelines from Specialist societies regarding 
recommendations for amounts and intensity of exercise/physical activity in NAFLD 
are variable. For example, the American Association for the Study of Liver Diseases 
(AASLD) Guideline does not make a specific recommendation about the amount or 
the desired intensity of exercise in NAFLD and states that ‘exercise alone in adults 
(with NAFLD) may reduce hepatic steatosis, but its ability to improve other aspects 
of liver histology are unknown[17]. The European Association for the Study of the 
Liver (EASL) recommends that in NAFLD guidelines for patients with type 2 diabetes 
are followed and recommends 150 minutes per week of moderate intensity 
exercise[18] and this recommendation is largely in keeping with guidelines for the 
general population[19]. Thus, at present it is unclear how much exercise is needed 
or how intense that exercise should be to prevent development of new fatty liver or to 
resolve existing fatty liver. We have utilized a retrospective study design of an 
occupational cohort in which there were measurements of exercise/physical activity 
at baseline and at follow up (as key exposures) with measurements of fatty liver 
assessed by ultrasonography at baseline and at follow up (as the key outcomes) to 
assess relationships between exercise and change in fatty liver status over time. 
Although ultrasonography has limited sensitivity to detect liver fat in NAFLD, liver 
ultrasonography is a good technique to assess whether liver fat is present, providing 
liver fat accumulation is approximately 30% [20, 21]. Since it remains uncertain how 
much exercise is needed, or for how long that exercise is needed, (to treat liver fat 
and to decrease risk of developing new liver fat), we have studied relationships 
between numbers of weekly exercise sessions at baseline and change in numbers of 
weekly exercise sessions between baseline and follow up, with both incident fatty 
liver at follow up and resolution of baseline fatty liver at follow up. Specifically, our 
aim was to determine the amount of baseline exercise that was associated with: a) 
decreased development of incident liver fat and b) resolution of baseline liver fat (as 
the outcomes of interest), at five year follow up. Additionally, we aimed to assess 
whether any increase in the number of exercise sessions between baseline and 
follow up was associated with these fatty liver-related outcomes at five year follow up 
after adjusting for key confounders that also included change in body mass index 
(BMI) between baseline and follow up.   
Methods 
Study population 
The Kangbuk Samsung Health Study is a cohort study of South Korean men and 
women 18 years of age or older who underwent a comprehensive annual or biennial 
health examination at the clinics of the Kangbuk Samsung Hospital Total Healthcare 
Center in Seoul and Suwon, South Korea. More than 80% of participants were 
employees of various companies and local governmental organizations and their 
spouses. In South Korea, the Industrial Safety and Health Law requires annual or 
biennial health screening examinations of all employees, offered free of charge. The 
remaining participants were subjects voluntarily taking part in the screening 
examinations. The study population consisted of individuals who participated in a 
comprehensive health screening program, at least twice, at Kangbuk Samsung 
Hospital, Seoul, Korea from 2002 to 2014 (n = 233,676). Among these subjects, to 
test relationships between exercise and incident fatty liver, and exercise and 
resolution of existing fatty liver, we excluded subjects in which there was missing 
data for smoking, exercise, fatty liver and cancer (n=19,613). Subjects were also 
excluded if they were HbsAg positive (n=9,297), HCV Ab positive (n=307), and daily 
alcohol consumption was more than 20g (men) and 10g (women) (n=38,296). Also 
for testing relationships with incident fatty liver at follow up subjects with baseline 
fatty liver (n=60,522) were excluded. Thus 126,811 subjects were included in this 
analysis and their mean±SD follow up period was 4.95±3.29) years. Relationships 
between exercise and resolution of fatty liver were examined in 42,536 individuals 
and subjects were included who had fatty liver at baseline. Mean±SD follow up was 
4.29 (3.26) years. The study was approved by the Institutional Review Board of 
Kangbuk Samsung Hospital and any requirement for informed consent was waived 
by the Board, because de-identified information was retrieved retrospectively. 
Measurements 
As part of the health screening program, individuals completed self-administered 
questionnaires, related to their medical and social history and medication use. 
Individuals were asked about duration of education (years), smoking history (never, 
former, or current) and alcohol consumption (grams, g/week). We assessed the 
weekly frequency of moderate- or vigorous-intensity physical activity which was 
assessed using the validated Korean version of the International Physical Activity 
Questionnaire Short Form (IPAQ-SF)[22]. The IPAQ-SF measures the frequency and 
duration of moderate to vigorous physical activity undertaken for more than 10 
continuous minutes across all usual activities at work, home or during leisure for 
middle aged individuals during a seven-day period. To assess the number of 
exercise sessions undertaken per week by each participant, the following specific 
questions were asked to gauge the number of times per week a participant engaged 
in exercise. "How many days did you undertake physical activity (enough to 
perspire)?" or “during the last seven days, on how many days did you do moderate 
intensity physical activity e.g. carrying light loads, bicycling at a steady pace, or 
playing tennis? Do not include walking in your response” If the answer was greater 
than zero, additional questions were asked such as “How much time did you usually 
spend doing moderate or vigorous physical activities on one of those days?” In our 
study, subjects were classified into four categories for analysis of exercise as the 
exposure with the outcomes of interest. No regular physical activity, exercise 1-2 
times per week, exercise 3-4 times per week and exercise ≥5 times per week. 
Additionally we defined change in exercise between baseline and follow up, 
according to a decrease, no change, or an increase in the number of weekly 
exercise sessions per week. 
Trained staff also collected anthropometric measurements and vital statistics. 
Body weight was measured in light clothing with no shoes to the nearest 0.1 
kilogram using a digital scale. Height was measured to the nearest 0.1 centimeter. 
Body mass index (BMI) was calculated as weight in kilograms divided by height in 
meters squared. Blood samples were collected after at least 10-hours of fasting and 
analyzed in the same core clinical laboratory. The core clinical laboratory has been 
accredited and participates annually in inspections and surveys by the Korean 
Association of Quality Assurance for Clinical Laboratories.  
Abdominal ultrasonography (Logic Q700 MR; GE, Milwaukee, WI, USA) was 
undertaken by clinical radiologists using a 3.5MHz probe for all subjects at baseline 
and after five years. The following images were undertaken; i) sagittal view of the 
right lobe of the liver and right kidney, ii) transverse view of the left lateral segment of 
the liver and spleen and iii) transverse view of the liver for altered echo texture. Fatty 
infiltration of the liver (fatty liver) was identified if there was an increase in 
echogenicity of the liver compared with the echogenicity of the renal cortex where 
the diaphragm and intrahepatic vessels appeared normal[21]  
 
Statistical analyses  
The statistical analysis was performed using STATA version 11.2 (StataCorp LP, 
College Station, TX, USA). Reported P values were two-tailed, and <0.05 were 
considered statistically significant. The distribution of continuous variables was 
evaluated and transformations were conducted for nonparametric variables. Cox 
proportional hazards models were used to estimate hazard ratios (HRs and 95% 
confidence intervals) for incident fatty liver and resolution of fatty liver. For testing 
linear risk trends across exercise groups in the regression models, we used the 
categories rank as a continuous variable. For each outcome, three regression 
models were generated. Model 1: adjustment for age, sex, center, year of screening 
exam, smoking status, alcohol intake, education level; model 2: model 1 adjustments 
plus adjustment for BMI, diabetes, hypertension (HTN), history of CVD ; model 3 
model 2+ BMI change. To test the effect of exercise change to the outcome we 
included adjustment for baseline exercise in model 3. 
 
  
Results 
233,676 men and women were studied between 2002 and 2014. 128,811 individuals 
were identified without fatty liver, and of these subjects, 97,797 remained free from 
fatty liver at follow up, whereas 29,014 subjects (22.5%) developed incident fatty 
liver during follow up. The baseline characteristics of the cohort according to the 
development of incident fatty liver at follow up are shown in Table 1. All traditional 
cardiovascular and metabolic risk factors were adversely affected in individuals who 
developed incident fatty liver at follow up examination, compared with subjects 
remaining free from fatty liver at follow up.   
Table 2 shows the baseline characteristics of the subjects according to four exercise 
groups (0, 1-2, 3-4 and ≥5 times per week). BMI was 0.9 kg/m2 higher in subjects 
exercising ≥5 times per week, compared with BMI in subjects who did not exercise. 
Also, in subjects exercising ≥5 times per week, mean ±SD systolic blood pressure 
was higher 113.4(14.0) mmHg compared with systolic blood pressure 109.6(12.6) 
mmHg in the subjects who did not exercise. Importantly there was no significant 
differences in change in BMI between baseline and follow up examination for the 
four different exercise groups. Surprisingly there was a slightly higher proportion of 
people with diabetes, hypertension and existing CVD in the highest exercise group. 
Table 3 shows the risk of incident fatty liver at follow up. After adjustment for all 
covariates and potential confounders (i.e. age, sex, center, year of screening exam, 
smoking status, alcohol intake, education level, BMI, diabetes, hypertension, CVD,  
and BMI change (between baseline and follow up)); compared with no exercise, any 
exercise was associated with benefit and reduced risk of development of incident 
fatty liver at follow up (E.g. for exercise ≥5 times per week for incident fatty liver: HR 
0.86 (95%CIs 0.8,0.92), p<0.001).  
 In clinically relevant sub groups the associations between exercise and incident fatty 
liver at follow up were investigated. Supplementary Table 1 shows the HRs for risk 
of incident fatty liver, in the four exercise groups (0, 1-2, 3-4 and ≥5 times per week) 
with no exercise as the reference group. Very similar results were noted regardless 
of subgroup and there were no significant sub-group by exercise group interactions. 
Since we showed there was a clear association between baseline exercise and 
development of incident fatty liver at follow up, even after adjusting for change in BMI 
between baseline and follow up, we investigated whether change in exercise 
(between baseline and follow up) was associated with development of incident fatty 
liver at follow up. Three exposure groups were generated according to whether there 
had been: a) a decrease in number of exercise sessions per week which was the 
reference group; b) no change in numbers of exercise sessions per week between 
baseline and end of study; and c) an increase in the number of exercise sessions per 
week between baseline and follow up. Table 4 shows associations between change 
in exercise and incident fatty liver at follow up. In the fully adjusted regression model 
that also included adjustment for change in BMI between baseline and end of study, 
in subjects in whom there was an increase in number of exercise sessions between 
baseline and follow up, there was a decreased risk of incident fatty liver at follow up 
[(HR 0.87, (95%CIs 0.82.0.93), p<0.001].      
At baseline, there were 42,536 individuals with baseline liver fat and of these 
individuals, fatty liver resolved in 14,514 (34.1%), during follow up. The baseline 
characteristics of the cohort according to the resolution of fatty liver at follow up is 
shown in Table 5. Between baseline and follow up there was a 0.5 kg/m2 decrease in 
BMI in subjects whom fat liver resolved between baseline and follow up examination, 
compared with a 0.1 kg/m2 increase in subjects in whom fatty liver was present at 
both baseline and follow up examination.  
Table 6 shows the association between different amounts of exercise and resolution 
of fatty liver at follow up. (N.B. all individuals included in these analyses had fatty 
liver at baseline examination). After adjustment for all covariates and potential 
confounders age, sex, center, year of screening exam, smoking status, alcohol 
intake, education level, BMI, diabetes, hypertension, CVD, hs CRP and BMI change 
(between baseline and follow up); compared with no exercise, any exercise was 
associated with benefit and resolution of fatty liver at follow up . E.g. for exercise ≥5 
times per week was associated with an increased HR for resolution of fatty liver at 
follow up HR 1.40 (95%CIs 1.25, 1.55), p<0.001.  
In clinically relevant sub groups the associations between exercise and resolution of 
fatty liver at follow up was investigated. Supplementary Table 2 shows the HRs for 
the associations between exercise and resolution of fatty liver, in the four exercise 
groups (0, 1-2, 3-4 and ≥5 times per week) with no exercise as the reference group. 
There were strong significant trends for the strength of the associations across 
exercise groups with resolution of fatty liver, with a stronger association between 
greater amounts of exercise and resolution of fatty liver. For both incident fatty liver 
(Supplementary Table 1) and resolution of existing fatty liver (Supplementary Table 
2), there was an interaction between male sex and both incident fatty liver and 
resolution of existing fatty liver, (although it should be noted that for men and women 
in each of the three exercise groups, the 95%Cis around the point estimates of the 
HRs overlapped between the sexes).  
 
Since we showed there was a clear association between baseline exercise and 
resolution of fatty liver at follow up, even after adjusting for change in BMI between 
baseline and follow up, we also investigated whether change in exercise (between 
baseline and follow up) was associated with resolution of fatty liver at follow up. As 
for the analyses examining associations between exercise and incident fatty liver, 
three exposure groups were generated according to whether there had been: a) a 
decrease in number of exercise sessions per week which was the reference group; 
b) no change in numbers of exercise sessions per week between baseline and end 
of study; and c) an increase in the number of exercise sessions per week between 
baseline and follow up. A decrease in exercise between baseline and end of study 
was the reference category. Table 7 shows associations between change in exercise 
and resolution of fatty liver at follow up. In the fully adjusted model, and after 
adjusting for change in BMI between baseline and follow up, in subjects in whom 
there was an increase in number of exercise sessions between baseline and follow 
up, there was a significant association with resolution of fatty liver at follow up [HR 
1.13, (95%CIs 1.03, 1.24), p=0.01].      
 
  
Discussion  
The novel results of our study are that any amount exercise is beneficial in either 
decreasing risk of development of new fatty liver, or in improving resolution of 
existing fatty liver, over 5 years of follow up. Additionally, and importantly, our data 
shows that over this period of follow up, any increase in the number of weekly 
exercise sessions was associated with both a decrease in risk of incident fatty liver 
and also in resolution of existing fatty liver. Given the accepted importance of losing 
weight to ameliorate liver fat in the treatment of overweight patients with NAFLD, we 
also adjusted for change in BMI between baseline and follow up. Our findings clearly 
showed that for both incident fatty liver and for resolution of existing fatty liver, 
relationships between exercise and fatty liver status were independent of any 
change in BMI during the follow up period. Furthermore, as can be seen from the 
regression models in Tables 3 and 6 (for incident fatty liver and resolution of fatty 
liver respectively), there were linear trends between increasing numbers of weekly 
exercise sessions and the outcomes of interest, with an increasing strength of 
association between exercise and fatty liver status, with increasing numbers of 
weekly exercise sessions.  
 
Interestingly, for both incident fatty liver (Supplementary Table 1) and resolution of 
existing fatty liver (Supplementary Table 2), there was an interaction between male 
sex and both incident fatty liver and resolution of existing fatty liver. It is important to 
be cautious in interpreting this result. Furthermore, it should be noted that for men 
and for women in each of the three exercise groups, the 95%CIs around the point 
estimates of the HRs overlapped between the sexes. Additionally, for resolution of 
fatty liver, the n number for women (n=7,572) was much smaller than it was for men 
(n=34,964). However, that said, we suggest more research is needed to test whether 
sex-exercise interactions exist to influence changes in fatty liver status over time.   
 
The available evidence to date suggests a benefit of exercise to decrease fatty liver 
in NAFLD [13-16, 23], and the question of the optimum prescribed 'dose' of exercise 
for all liver diseases [14] and the effect of aerobic exercise on liver fat [24] have 
recently been examined. These analyses show that it remains uncertain as to what 
exercise should be advised and how intense (and for how long), that exercise needs 
to be, in order to influence liver fat. We have therefore investigated the potential 
benefit of exercise on development of incident liver fat and resolution of existing liver 
fat in NAFLD in free-living individuals, because most evidence to date is limited to 
short term clinical trials with a supervised intervention. 
 
We acknowledge that a limitation of our study is that we do not have an objective 
assessment of exercise/physical activity in our cohort, our data show that any 
amount of exercise for >10 minutes per week is beneficial, compared with no 
exercise. Moreover, the validated Korean version of the International Physical 
Activity Questionnaire Short Form (IPAQ-SF)[22] measures not only the frequency, 
but also provides information about the relative intensity of the exercise. The 
questionnaire asks about the number of weekly exercise sessions where participants 
participate in moderate to vigorous physical activity undertaken for more than 10 
continuous minutes either at work, home or during leisure. Thus, although we 
conclude from our data that any exercise is beneficial (to affect the specified NAFL 
outcomes), it is also possible to qualify this conclusion by stating that any moderate 
to vigorous physical activity lasting at least 10 mins per week is beneficial to affect 
these liver fat outcomes. Self-reported measures of recalled physical activity levels 
are prone to overestimation of the recalled amount of exercise. However, it 
reassuring to note that we have observed linear trends between the amount of 
exercise and most cardiovascular and metabolic risk factors, with a suggested ‘dose-
response’ effect indicating a more favorable cardio-metabolic profile in subjects 
reporting higher levels of exercise. We are not able to take account of an individual 
altering the number of their weekly exercise sessions and at the same time altering 
the intensity of this weekly exercise, during the follow up period.  
 
Additionally, although there are better techniques than ultrasound such as magnetic 
resonance imaging for quantifying subtle changes in liver fat with exercise[25], it was 
not possible to use magnetic resonance techniques in this many subjects, and 
ultrasound can be used to assess whether liver fat is present or not if levels of liver 
fat are approximately 30%. Furthermore, imprecision in the measurement of both the 
exposure and the outcome, would possibly result in some misclassification of the 
exercise-related exposures and the liver-related outcomes . However, that said, it is 
important to recognize that resulting misclassification bias would attenuate the 
strengths of our findings and would bias the results towards the null. That we 
observe independent, consistent and graded associations between amounts of 
exercise and our liver fat outcomes of interest, provides confidence that these 
associations have not arisen by chance. We have also adjusted for key confounders 
and in particular change in BMI between baseline and follow up, and in this very 
large cohort there are no other obvious causes of bias that might have produced 
these results.   
 
Studies that have shown a benefit of exercise to decrease liver fat have tended to be 
very short term interventions and have used very variable exercise regimes such as 
2-3 sessions of exercise a week for 30-60 minutes of exercise[17]. Other 
interventional studies have tested and shown a benefit of short term resistance 
training in NAFLD[26] but it remains uncertain what amount and how intense the 
exercise or physical activity needs to be to both decrease existing liver fat and to 
decrease risk of development of new cases of non alcoholic fatty liver (NAFL). Based 
on the presented results, how might moderate to vigorous physical activity reduce 
the level of existing liver fat or alteratively decrease risk of liver fat developing in 
NAFLD, independently of weight loss? It is known from animal studies that chronic 
exercise decreases liver fat by reducing the activity of key enzymes in hepatic lipid 
synthesis such as acetyl CoA carboxylase (ACC) and fatty acid synthesis [27]. A 
reduction in activity of these enzymes would result in decreased triglyceride 
accumulation and a decrease in liver fat. It is also plausible that the more physically 
active subjects in our study had better cardiorespiratory fitness with better skeletal 
muscle and cardiac muscle fatty acid oxidation resulting in diminished substrate flux 
(of fatty acids) to the liver for hepatic triglyceride synthesis [28]. In support of a 
relationship between higher levels of physical activity and greater cardiorespiratory 
fitness in NAFLD, a 16 week supervised exercise program to intervene with modest 
exercise in middle aged patients with NAFLD, showed that not only did liver fat 
percentage decrease, but also V02 max was improved, by the modest limited 
duration exercise intervention of 16 weeks duration [23].    
 
In conclusion, these data show that any amount moderate weekly exercise lasting at 
least 10 minutes was beneficial in either decreasing risk of development of new fatty 
liver, or in improving resolution of existing fatty liver, over 5 years of follow up. During 
follow up, any increase in the number of weekly exercise sessions was associated 
with both a decrease in risk of incident fatty liver and resolution of existing fatty liver, 
and these associations were independent of any change in BMI during the period of 
follow up.  
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Table 1. Baseline characteristics of the cohort according to incident fatty liver 
at follow up 
 
Baseline characteristics 
NO  FATTY LIVER P 
Number 97,797 29,014  
N (%) Men 40.1 70.2  
Age (years) 36.9(7.7) 37.5(7.5) <0.001
BMI (kg/m2) 21.8(2.5) 23.9(2.5) <0.001
Systolic BP (mmHg) 109.9(12.8) 114.4(12.9) <0.001
Diastolic BP (mmHg) 70.5(9.2) 74.1(9.5) <0.001
Higher education (%)a 75.9 77.9 <0.001
Current smoker 17.0 31.3 <0.001
Alcohol intake (g/day)  3(0-6) 4(0-10) <0.001
Obesity (%)b 10.0 30.2 <0.001
Insulin (IU/mL) 4.09(2.85-5.7) 5.12(3.61-7.07) <0.001
Glucose (mg/dl) 91.0(10.2) 93.3(12.1) <0.001
Total cholesterol (mg/dl) 185.7(32.0) 196.2(33.4) <0.001
LDL-C (mg/dl) 105.8(27.3) 117.0(28.3) <0.001
HDL-C (mg/dl 59.2(12.9) 53.0(11.2) <0.001
Triglycerides (mg/dl) 80(61-109) 113(82-156) <0.001
HOMA IR 1.50(1.08-1.98) 1.76(1.32-2.27) <0.001
Hs-CRP (mg/L) 0.3(0.1-0.6) 0.5(0.2-1.0) <0.001
Diabetes (%) 1.0 1.9 <0.001
Hypertension  (%) 7.3 13.4 <0.001
Cardiovascular disease  (%) 3.2 2.9 0.001 
BMI change between baseline and follow up 0.1(1.0) 0.5(1.1) <0.001
 
a ≥college graduate 
b BMI≥ 25
 
Table 2. Baseline characteristics of study subjects according to the numbers of exercise sessions per week 
Characteristics Overall Exercise sessions (per week) P for 
trend 0 1-2 3-4 ≥5  
N=  126,811 73,313 33,877 13,816 5,805  
Age (years) 40.5(9.7) 36.1(7.1) 37.6(7.7) 39.3(8.4) 40.5(9.7) <0.001 
Men (%) 47.0 38.8 63.0 51.7 45.7 <0.001 
BMI (kg/m2) 22.2(2.6) 21.9(2.6) 22.7(2.5) 22.9(2.5) 22.8(2.5) <0.001 
Systolic BP (mmHg) 110.9(13.0) 109.6(12.6) 112.7(13.0) 112.9(13.5) 113.4(14.0) <0.001 
Diastolic BP (mmHg) 71.3(9.4) 70.3(9.2) 72.7(9.4) 72.8(9.6) 72.9(9.6) <0.001 
Higher education (%) 76.4 76.1 79.3 74.2 67.5 <0.001 
Current smoker 20.3 17.7 25.5 19.5 22.9 <0.001 
Alcohol intake  g/day 3(0-6) 2(0-6) 3(0-9) 3(0-8) 3(0-6) <0.001 
Obesity (%) 14.7 11.9 18.0 19.4 18.7 <0.001 
Insulin (IU/ml) 4.23(2.95-5.91) 4.3(2.99-6.01) 
4.19(2.93-
5.88) 
4.08(2.83-
5.61) 
3.91(2.71-
5.53) <0.001 
Glucose (mg/dl) 91.5(10.7) 90.9(9.7) 92.1(12.0) 92.2(11.5) 92.8(13.0) <0.001 
Total cholesterol (mg/dl) 188.1(32.7) 186.1(32.5) 190.(32.6) 191.3(32.7) 191.7(33.0) <0.001 
LDL-C (mg/dl) 108.4(28.0) 106.9(27.9) 110.8(27.9) 110.2(27.9) 109.0(28.0) <0.001 
HDL-C (mg/dl 57.8(12.8) 58.0(12.8) 56.6(12.4) 58.5(13.0) 60.4(13.8) <0.001 
Triglycerides (mg/dl) 86(64-120) 84(63-117) 92(68-128) 86(64-119) 80(60-112) <0.001 
HOMA IR 1.56(1.13-
2.05) 
1.56(1.13-
2.06) 
1.56(1.14-
2.04) 
1.55(1.15-
2.03) 
1.50(1.09-
1.98) 0.038 
Hs-CRP(mg/L) 0.3(0.1-0.7) 0.3(0.1-0.7) 0.4(0.1-0.8) 0.3(0.1-0.7) 0.3(0.1-0.7) <0.001 
Diabetes  (%) 1.2 0.8 1.4 2.2 3.3 <0.001 
Hypertension  (%) 8.7 6.7 10.5 12.2 13.7 <0.001 
Cardiovascular disease 
(%) 3.1 2.9 2.9 4.1 5.0 <0.001 
BMI change between 
baseline and follow up 0.2(1.0) 0.2(1.1) 0.2(1.0) 0.2(1.0) 0.2(1.1) 0.272 
 
 
 Table 3. Risk of incident fatty liver according to baseline number of exercise sessions (per week) 
Exercise 
sessions (per 
week) 
Person-
years 
Number 
of 
events 
incident 
(100,000 
person-
year) 
Age-sex 
adjusted HR 
(95% CI) 
Multivariate HR*(95% CI)  
Model 1 Model 2 Model 3 
 Incident 
fatty liver 
Incident 
fatty liver
Incident 
fatty liver 
    
0 371,025.9 15,083 4,065.2 1.00(reference) 1.00(reference) 1.00(reference) 1.00(reference)
1-2 163,943.7 9,220 5,623.9 1.04(1.01-1.07) 1.04(1.00-1.07) 0.94(0.91-0.97) 0.93(0.90-0.96)
3-4 66,092.2 3,488 5,217.0 1.06(1.02-1.10) 1.07(1.02-1.12) 0.90(0.86-0.94) 0.87(0.83-0.91)
≥5  27,148.6 1,263 4,652.2 0.98(0.93-1.04) 1.03(0.96-1.11) 0.90(0.84-0.97) 0.86(0.80-0.92)
P for trend    0.026 0.004 <0.001 <0.001 
 
*Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, education level;  
*Model 2: model 1 adjustments plus adjustment for BMI, diabetes, HTN, CVD 
*Model 3: model 2 adjustments plus adjustment for change in BMI between baseline and follow up  
 
 
  
Table 4. Risk of incident fatty liver according to change in number of exercise sessions per week between baseline and 
follow up 
Change in 
Exercise 
sessions (per 
week) 
Person-
years 
Number 
of events 
incident 
rate 
(100,000 
person-
year) 
Age-sex 
adjusted HR 
(95% CI) 
Multivariate HR*(95% CI)  
Model 1 Model 2 
 
Model 3 
 Incident 
fatty liver 
Incident 
fatty liver
Incident 
fatty liver
    
Decrease 98,995.2 3,458 349.3 1.00(reference) 1.00(reference) 1.00(reference) 1.00(reference) 
No change 284,527.8 8,291 2,914.0 0.89(0.85-0.92) 0.91(0.87-0.96) 0.93(0.89-0.98) 
0.95(0.90-1.00) 
Increase 120,597.5 3,582 2,970.2 0.89(0.85-0.93) 0.90(0.84-0.95) 0.84(0.79-0.89) 
0.87(0.82-0.93) 
P for trend    <0.001 0.001 <0.001 <0.001 
 
*Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, education level and number of baseline exercise sessions.  
*Model 2: model 1 adjustments plus adjustment for BMI, diabetes, hypertension, history of CVD 
*Model 3: model 2 adjustments plus adjustment for change in BMI between baseline and follow up.  
 
  
Table 5. Baseline characteristics of the cohort according to resolution of fatty 
liver follow up 
 
Baseline characteristics 
Fatty liver at 
baseline and at 
follow up  
Fatty liver at 
baseline but not 
at follow up 
P 
Number 28,022 14,514  
N (%) Men 84.5 77.8  
Age (years) 39.1(8.6) 39.0(8.4) 0.628 
BMI (kg/m2) 26.2(2.8) 25.5(2.7) <0.001
Systolic BP (mmHg) 118.9(13.4) 117.8(13.7) <0.001
Diastolic BP (mmHg) 77.4(9.7) 76.6(9.8) <0.001
Higher education (%)a 81.4 78.7 <0.001
Current smoker 35.5 31.3 <0.001
Alcohol intake      g/day  6(0-11) 5(0-11) 0.089 
Obesity (%) 64.8 54.8 <0.001
Insulin (IU/mL) 7.22(5.19-9.98) 6.09(4.4-8.53) <0.001
Glucose (mg/dl) 99.2(19.5) 98.3(19.2) <0.001
Total cholesterol (mg/dl) 208.8(35.2) 206.5(35.0) <0.001
LDL-C (mg/dl) 128.4(30.6) 124.9(30.0) <0.001
HDL-C (mg/dl 48.3(9.4) 50.2(10.2) <0.001
Triglycerides (mg/dl) 156(113-216) 142(104-197) <0.001
HOMA IR 2.27(1.68-3.00) 2.11(1.57-2.74) <0.001
Hs-CRP (mg/L) 0.8(0.4-1.5) 0.7(0.4-1.3) <0.001
Diabetes  (%) 6.4 5.4 <0.001
Hypertension  (%) 23.4 21.3 <0.001
Cardiovascular disease (%) 4.6 3.9 0.001 
Change in BMI between baseline and 
follow up 0.1(1.0) -0.5(1.2) <0.001
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Table 6.  Associations between number of sessions of exercise per weeks and resolution of fatty liver at follow up  
Exercise 
sessions 
(per week) 
Person-
years 
Number 
of events
incident 
(100,000 
person-
year) 
Age-sex 
adjusted 
HR (95% CI)
Multivariate HR*(95% CI)  
Model 1 Model 2 Model 3 
 Resolution 
of fatty 
liver 
Resolution 
of fatty 
liver 
Resolution 
of fatty liver 
    
0 98,400.7 7,677 7,801.8 1.00(reference) 1.00(reference) 1.00(reference) 1.00(reference) 
1-2 
60,514.3 4,699 7,765.1 1.04(1.00-1.08) 1.03(0.98-1.07) 1.05(1.01-1.10) 1.05(1.01-  1.10) 
 
3-4 17,872.4 1,571 8,790.1 1.10(1.04-1.16) 1.07(1.00-1.15) 1.10(1.03-1.18) 1.18(1.10- 1.26) 
≥5  5,556.2 567 10,204.8 1.19(1.09-1.30) 1.21(1.08-1.34) 1.26(1.14-1.41) 1.40(1.25- 1.55) 
P for trend    <0.001 0.001 <0.001 <0.001 
 
*Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, education level;  
*Model 2: model 1 adjustments plus adjustment for BMI, diabetes, hypertension, CVD 
*Model 3: model 2 adjustments plus adjustment for change in BMI between baseline and end of study 
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Table 7.   Associations between change in numbers of weekly exercise sessions and resolution of fatty liver at follow 
up  
Change in 
Exercise 
sessions (per 
week) 
Person-
years 
Number 
of 
events 
Disappear 
rate 
(100,000 
person-
year) 
Age-sex 
adjusted 
HR (95% CI) 
Multivariate HR*(95% CI)  
Model 1 Model 2 
 
Model 3 
 Resolution 
of fatty 
liver 
Resolution 
of fatty 
liver 
Resolution 
of fatty liver 
    
Decrease 32,215.8 1,359 4,218.4 1.00(reference) 1.00(reference) 1.00(reference) 1.00(reference)
No change 75,345.3 3,354 445.2 1.04(0.98-1.11) 1.07(0.98-1.16) 1.06(0.98-1.16) 1.05(0.96-1.14)
Increase 35,096.6 1,675 4,772.6 1.12(1.04-1.20) 1.17(1.07-1.29) 1.18(1.07-1.30) 1.13(1.03-1.24)
P for trend    0.002 0.001 <0.001 0.010 
 
*Model 1: adjustment for age, sex, center, year of screening exam, smoking status, alcohol intake, education level and number of weekly baseline exercise 
sessions 
*Model 2: model 1 adjustments plus adjustment for BMI, diabetes, hypertension, history of CVD 
*Model 3: model 2 adjustments plus adjustment for change in BMI between baseline and follow up 
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SUPPLEMENTARY TABLES 
Supplementary Table 1. Risk of incident fatty liver according to exercise group in clinically relevant subgroups. 
 
 
Exercise (per week) p for 
trend 
p for 
interaction 0 1-2 3-4 ≥5  
       
Men (n=59,618) 1.00(reference) 0.90(0.87-0.94) 0.85(0.81-0.90) 0.86(0.78-0.93) <0.001 0.000 
aHR (95% CI)       
Women (n=67,193) 1.00(reference) 1.03(0.96-1.09) 0.96(0.88-1.05) 0.89(0.79-1.00) 0.826  
aHR (95% CI)       
Age <50 years (n=117,937) 1.00(reference) 0.94(0.91-0.97) 0.89(0.85-0.93) 0.90(0.84-0.97) 0.001 0.244 
aHR (95% CI)       
Age ≥50 years (n=8,874) 1.00(reference) 0.89(0.77-1.02) 0.87(0.74-1.02) 0.83(0.69-1.01) 0.096  
aHR (95% CI)       
Non or ever smoker(n=101,133) 1.00(reference) 0.95(0.92-0.99) 0.88(0.83-0.93) 0.85(0.78-0.92) 0.014 0.127 
aHR (95% CI)       
Current smoker(n=25,678) 1.00(reference) 0.90(0.85-0.95) 0.88(0.81-0.96) 0.90(0.79-1.03) <0.001  
aHR (95% CI)       
<college graduate(n=20,147) 1.00(reference) 0.94(0.88-1.01) 0.87(0.79-0.95) 0.86(0.76-0.98) 0.136 0.964 
aHR (95% CI)       
≥college graduate(n=65,227) 1.00(reference) 0.92(0.89-0.96) 0.87(0.83-0.92) 0.85(0.78-0.93) <0.001  
aHR (95% CI)       
HTN NO 1.00(reference) 0.93(0.90-0.96) 0.85(0.81-0.90) 0.86(0.80-0.93) <0.001 0.430 
aHR (95% CI)       
HTN YES 1.00(reference) 0.94(0.86-1.03) 0.97(0.86-1.08) 0.86(0.73-1.01) 0.070  
aHR (95% CI)       
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DM NO 1.00(reference) 0.93(0.90-0.96) 0.87(0.83-0.91) 0.86(0.80-0.92) <0.001 0.902 
aHR (95% CI)       
DM YES 1.00(reference) 0.96(0.74-1.25) 1.01(0.75-1.35) 0.95(0.66-1.38) 0.688  
aHR (95% CI)       
CVD NO 1.00(reference) 0.93(0.90-0.96) 0.87(0.83-0.91) 0.86(0.80-0.92) <0.001 0.148 
aHR (95% CI)       
CVD YES 1.00(reference) 1.51(0.97-2.37) 1.39(0.83-2.33) 1.15(0.59-2.21) 0.226  
aHR (95% CI)       
Homa75=0 (n=107,849) 1.00(reference) 0.93(0.90-0.96) 0.87(0.82-0.91) 0.87(0.80-0.94) <0.001 0.124 
aHR (95% CI)       
Homa75=1 (n=15,638)  1.00(reference) 0.97(0.90-1.05) 1.03(0.92-1.16) 0.85(0.71-1.02) 0.183  
aHR (95% CI)       
BMI <25 kg/m2 (n=108,230) 1.00(reference) 1.01(0.97-1.05) 0.99(0.93-1.04) 0.89(0.82-0.98) 0.840 0.010 
aHR (95% CI)       
BMI ≥25 kg/m2 (n=18,570) 1.00(reference) 0.96(0.91-1.02) 0.96(0.89-1.03) 0.99(0.88-1.11) 0.338  
aHR (95% CI)       
CRP>1.0 (n=102,380) 1.00(reference) 0.92(0.89-0.96) 0.87(0.82-0.91) 0.85(0.78-0.92) <0.001 0.705 
aHR (95% CI)       
CRP<1.0 (n=23,458) 1.00(reference) 0.95(0.89-1.01) 0.82(0.84-1.01) 0.91(0.78-1.05) 0.106  
aHR (95% CI)       
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Supplementary Table 2. Associations between exercise group and resolution of fatty liver at follow up in clinically 
relevant subgroups. 
 
 Exercise (per week) p for 
trend 
p for 
interaction 
0 1-2 3-4 ≥5  
       
Men (n=34,964) 1.00(reference) 1.07(1.02-1.12) 1.22(1.13-1.31) 1.36(1.20-1.54) 0.002 0.007 
aHR (95% CI)       
Women (n=7,572) 1.00(reference) 0.99(0.89-1.10) 1.04(0.89-1.20) 1.43(1.16-1.75) 0.416  
aHR (95% CI)       
Age <50 years (n=37,634) 1.00(reference) 1.05(1.00-1.10) 1.17(1.09-1.26) 1.31(1.16-1.49) 0.011 0.007 
aHR (95% CI)       
Age ≥50 years (n=4,902) 1.00(reference) 1.13(0.96-1.32) 1.34(1.12-1.60) 1.75(1.40-2.18) 0.016  
aHR (95% CI)       
Non or ever smoker(n=28,053) 1.00(reference) 1.03(0.98-1.09) 1.15(1.06-1.24) 1.48(1.30-1.68) 0.021 0.067 
aHR (95% CI)       
Current smoker(n=14,483) 1.00(reference) 1.10(1.02-1.19) 1.29(1.14-1.47) 1.25(1.02-1.52) 0.024  
aHR (95% CI)       
<college graduate(n=5,450) 1.00(reference) 1.04(0.94-1.15) 1.17(1.01-1.35) 1.62(1.34-1.97) 0.063 0.449 
aHR (95% CI)       
≥college graduate(n=22,342) 1.00(reference) 1.05(1.00-1.10) 1.17(1.08-1.26) 1.29(1.13-1.47) 0.035  
aHR (95% CI)       
HTN NO 1.00(reference) 1.07(1.01-1.12) 1.16(1.07-1.26) 1.34(1.18-1.52) 0.003 0.764 
aHR (95% CI)       
HTN YES 1.00(reference) 1.03(0.94-1.14) 1.21(1.06-1.38) 1.53(1.25-1.87) 0.155  
aHR (95% CI)       
DM NO 1.00(reference) 1.05(1.01-1.10) 1.18(1.10-1.27) 1.42(1.27-1.59) 0.002 0.702 
aHR (95% CI)       
DM YES 1.00(reference) 1.07(0.88-1.31) 1.04(0.81-1.35) 1.11(0.76-1.62) 0.438  
aHR (95% CI)       
34 
 
CVD NO 1.00(reference) 1.06(1.01-1.10) 1.18(1.10-1.26) 1.39(1.24-1.55) 0.002 0.801 
aHR (95% CI)       
CVD YES 1.00(reference) 0.90(0.54-1.52) 1.04(0.53-2.04) 1.72(0.79-3.74) 0.879  
aHR (95% CI)       
Homa75=0 (n=24,534) 1.00(reference) 1.06(1.00-1.12) 1.12(1.03-1.22) 1.33(1.17-1.52) 0.008 0.297 
aHR (95% CI)       
Homa75=1 (n=16,981)  1.00(reference) 1.03(0.96-1.12) 1.28(1.13-1.44) 1.47(1.21-1.79) 0.212  
aHR (95% CI)       
BMI <25 kg/m2 (n=16,438) 1.00(reference) 1.03(0.96-1.10) 1.15(1.03-1.27) 1.36(1.14-1.61) 0.214 0.886 
aHR (95% CI)       
BMI ≥25 kg/m2 (n=26,095) 1.00(reference) 1.04(0.98-1.11) 1.16(1.06-1.27) 1.33(1.16-1.53) 0.057  
aHR (95% CI)       
 
 
 
 
